Enquiries about Vivli Member Studies
English
Canada, Toronto
Vivli

数据描述

Enquiries about Vivli Member Studies

The dataset is a collection of Vivli member study listings and related access information, covering studies available through the Vivli Platform as well as guidance for enquiring about studies not yet listed. It contains study-level availability details, instructions for submitting enquiries or data access requests, account requirements for platform use, and notes on member-specific submission processes and response discretion. Its purpose is to support researchers and other users in identifying relevant clinical study data, obtaining additional study information, and requesting access to shared datasets, while reflecting member policies such as limits on sharing studies before primary completion.

vivli.org
IP: 162.159.135.42
访问数据源
加载中...

相关论文

29

Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status

Sandro PignataAmit OzaGeoff HallBeatriz PardoRadoslaw Madry20
British Journal Of Cancer
2025
2025/3/17
00 p.1-8
The open-label, single-arm, multicentre ORZORA trial (NCT02476968) evaluated maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) with a germline (g) or somatic (s) BRCA1 and/or BRCA2 mutation (BRCAm) or a non-BRCA homologous recombination repair mutation (non-BR...
Medical researchOncology
10.1038/S41416-025-02966-X
ISSN:0007-0920

Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trial

Shabir A. MadhiHasra SnaggsZahra SkogebyYe FengShaun Barnabas18
Nature Medicine
2026
2026/7/28
00 p.1-12
Group B Streptococcus (GBS) disease is a major cause of infant morbidity and mortality. Capsular polysaccharide conjugate GBS vaccines have been evaluated for decades; however, none is licensed. This phase 1/2 trial evaluated an investigational maternal hexavalent polysaccharide−protein conjugate GB...
Bacterial infectionDiseasesPaediatricsVaccines
10.1038/S41591-026-04558-5
ISSN:1078-8956

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Neil H. SegalIgnacio MeleroVictor MorenoNeeltje SteeghsAurelien Marabelle24
Nature Communications
2024
2024/5/15
Vol.15 No.1 p.1-14
Cibisatamab is a bispecific antibody-based construct targeting carcinoembryonic antigen (CEA) on tumour cells and CD3 epsilon chain as a T-cell engager. Here we evaluated cibisatamab for advanced CEA-positive solid tumours in two open-label Phase 1 dose-escalation and -expansion studies: as a single...
Antibody therapyCancer immunotherapyColon cancer
10.1038/S41467-024-48479-8
ISSN:2041-1723

Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer

Popat SanjayLiu Stephen V.Scheuer NicolasHsu Grace G.Lockhart Alexandre8
Nature Communications
2022
2022/6/17
Vol.13 No.1 p.1-10
As advanced non-small cell lung cancer (aNSCLC) is being increasingly divided into rare oncogene-driven subsets, conducting randomised trials becomes challenging. Using real-world data (RWD) to construct control arms for single-arm trials provides an option for comparative data. However, non-randomi...
Lung cancerNon-small-cell lung cancerOutcomes research
10.1038/S41467-022-30908-1
ISSN:2041-1723

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

Wilkins DeidreYuan YuanChang YueAksyuk Anastasia A.Núñez Beatriz Seoane11
Nature Medicine
2023
2023/4/24
00 p.1-8
Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion conformation of the respiratory syncytial virus (RSV) F protein, which has been studied in preterm and full-term infants in the phase 2b and phase 3 MELODY trials. We analyzed serum samples collected from 2,143 infant...
ImmunizationVaccinesViral infection
10.1038/S41591-023-02316-5
ISSN:1078-8956

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

Nadia HarbeckEva CiruelosGuy JerusalemVolkmar MüllerNaoki Niikura22
Nature Medicine
2024
2024/9/13
00 p.1-10
Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (mBC) and stable or active (untreated/previously treated and progressing) brain metastases...
Breast cancer
10.1038/S41591-024-03261-7
ISSN:1078-8956

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

Benkeser DavidFong YouyiJanes Holly E.Kelly Elizabeth J.Hirsch Ian40
Npj Vaccines
2023
2023/3/11
Vol.8 No.1 p.1-13
In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the U.S., Chile, and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured four weeks after two doses were assessed as correlates of risk and protection aga...
Adaptive immunityInfectious diseasesVaccinesViral infection
10.1038/S41541-023-00630-0
ISSN:2059-0105

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Chmielecki JuliannMok TonyWu Yi-LongHan Ji-YounAhn Myung-Ju16
Nature Communications
2023
2023/2/27
Vol.14 No.1 p.1-8
Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. This analysis evaluates acquired resistance mechanisms to second-line osimertinib (n = 78) in patients with EGFR T790M ad...
CancerLung cancerTargeted therapies
10.1038/S41467-023-35962-X
ISSN:2041-1723

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

Bardia AdityaChandarlapaty SaratLinden Hannah M.Ulaner Gary A.Gosselin Alice17
Nature Communications
2022
2022/7/15
Vol.13 No.1 p.1-15
AMEERA-1 is a Phase 1/2 open-label single-arm study evaluating once-daily (QD) amcenestrant, an orally bioavailable selective estrogen receptor (ER) degrader, in postmenopausal women with ER+/HER2− advanced breast cancer (NCT03284957), who were mostly heavily pretreated (including targeted therapies...
Breast cancerCancer genomicsCancer therapeutic resistance
10.1038/S41467-022-31668-8
ISSN:2041-1723

A machine learning approach to population pharmacokinetic modelling automation

Sam RichardsonItziar Irurzun AranaAndrzej NowojewskiDiansong ZhouJacob Leander8
Communications Medicine
2025
2025/7/31
Vol.5 No.1 p.1-10
Population pharmacokinetic (PopPK) models are crucial for understanding drug behaviour across populations, yet traditional development is often labour-intensive and slow. This study demonstrates an automated, out-of-the-box approach for popPK model development, leveraging optimisation algorithms imp...
Clinical pharmacologyPharmacokinetics
10.1038/S43856-025-01054-8
ISSN:2730-664X

Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial

Tina CasconeLaura BonannoFlorian GuisierAmelia InsaMoishe Liberman25
Nature Medicine
2025
2025/5/31
00 p.1-9
In the phase II NeoCOAST-2 platform study, 202 patients with untreated, resectable stage IIA–IIIB non-small-cell lung cancer (NSCLC) were randomized to receive neoadjuvant durvalumab plus platinum-doublet chemotherapy with oleclumab, a CD73 inhibitor (Arm 1), or with monalizumab, a NKG2A inhibitor (...
ImmunotherapyNon-small-cell lung cancer
10.1038/S41591-025-03746-Z
ISSN:1078-8956

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

Salvatore SienaKanwal RaghavToshiki MasuishiKensei YamaguchiTomohiro Nishina19
Nature Communications
2024
2024/11/25
Vol.15 No.1 p.1-12
DESTINY-CRC01 (NCT03384940) was a multicentre, open-label, phase 2 study that investigated the safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing metastatic colorectal cancer (CRC). The present exploratory biomarker analy...
CancerPredictive markersTargeted therapies
10.1038/S41467-024-53223-3
ISSN:2041-1723

Systematic review of evidence on feasibility of administering intranasal live attenuated influenza vaccine at home

Ravi JhaveriNeil SkolnikAllyn Bandell
Npj Vaccines
2025
2025/11/23
0
In the United States, influenza vaccination coverage in adults and children remains below target, with disparities across racial and ethnic groups and setting urbanicity. Reducing barriers to influenza vaccination may improve coverage. Live attenuated influenza vaccine (LAIV) recently gained United ...
Drug regulationLive attenuated vaccines
10.1038/S41541-025-01324-5
ISSN:2059-0105

Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer

Melissa L. JohnsonGiulia FabbriCarmela CiardulloJudy S. WangGerald S. Falchook25
British Journal Of Cancer
2026
2026/4/3
00 p.1-13
Aurora kinase B (AURKB) is overexpressed in lung cancer and is associated with poor prognosis. AZD2811 is an AURKB inhibitor that demonstrated tolerability during a Phase I dose-escalation study in patients with advanced solid tumours, including small-cell lung cancer (SCLC). Here we report the dose...
Small-cell lung cancerTumour biomarkers
10.1038/S41416-026-03414-0
ISSN:0007-0920

The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results

Gail D. LewisGuangmin LiJun GuoShang-Fan YuCarter T. Fields31
Nature Communications
2024
2024/1/11
Vol.15 No.1 p.1-15
Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. To develop a differentiated HER2 ADC, we chose an antibody that does not compete with trastuzumab or pertuzumab for binding, conjugated to a reduced potency PBD (pyrrolo...
Breast cancerCancerDrug development
10.1038/S41467-023-44533-Z
ISSN:2041-1723

Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2

Jason P. LaliberteYingyun CaiTara KennyYi ZhangKuishu Ren29
Npj Vaccines
2025
2025/12/13
0
The COVID-19 pandemic spurred mRNA vaccine innovation, but new SARS-CoV-2 variants highlight the need for vaccines with improved potency and durability. This report presents a novel mRNA vaccine platform encoding virus-like particle antigens (mRNA-VLPs) that mimic native virus structures, aiming to ...
BiotechnologyImmunologyMicrobiology
10.1038/S41541-025-01303-W
ISSN:2059-0105

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Chmielecki JuliannGray Jhanelle E.Cheng YingOhe YuichiroImamura Fumio15
Nature Communications
2023
2023/2/27
Vol.14 No.1 p.1-9
Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimertinib improved outcomes vs comparator EGFR-TKIs in EGFRm ad...
CancerLung cancerTargeted therapies
10.1038/S41467-023-35961-Y
ISSN:2041-1723

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

Bahar AhaniKevin M. TuffyAnastasia A. AksyukDeidre WilkinsMichael E. Abram21
Nature Communications
2023
2023/7/19
Vol.14 No.1 p.1-10
Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV season. In this pre-specified analysis, isolat...
AntibodiesBiological therapyPaediatric researchViral infection
10.1038/S41467-023-40057-8
ISSN:2041-1723

Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study

David PriceMaarten J. H. I. BeekmanWalter Javier MattaruccoRocio Martina Barriga-AcevedoHao-Chien Wang11
Npj Primary Care Respiratory Medicine
2024
2024/11/1
Vol.34 No.1 p.1-10
This post-hoc analysis of the SABINA III study evaluated the association of short-acting β2-agonist (SABA) prescriptions and self-reported over-the-counter (OTC) SABA purchase in the previous 12 months with asthma-related outcomes using multivariable regression models in 4556 patients (mean age, 48....
AsthmaHealth policy
10.1038/S41533-024-00397-4
ISSN:2055-1010

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer

Roy S. HerbstThomas JohnChristian GrohéJonathan W. GoldmanTerufumi Kato23
Nature Medicine
2025
2025/3/17
00 p.1-11
Osimertinib—a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor—is recommended as adjuvant therapy for resected stage IB–IIIA epidermal growth factor receptor-mutated non-small-cell lung cancer, based on significant disease-free survival (DFS) and overall survival improveme...
Lung cancerNon-small-cell lung cancer
10.1038/S41591-025-03577-Y
ISSN:1078-8956

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Takayuki YoshinoMaria Di BartolomeoKanwal RaghavToshiki MasuishiFotios Loupakis20
Nature Communications
2023
2023/6/7
Vol.14 No.1 p.1-13
DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens; results of the primary analysis are published. Pa...
Colorectal cancerMetastasisTargeted therapies
10.1038/S41467-023-38032-4
ISSN:2041-1723

A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19

Rhiannon EdgeSam MatthewsBahar AhaniAnastasia A. AksyukLindsay Clegg18
Nature Communications
2025
2025/10/14
Vol.16 No.1 p.1-14
Clinical development of monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is challenging due to rapid changes in the variant landscape. This study identified a threshold model for neutralising antibody (nAb) titres associated with clinically relevant p...
AntibodiesTranslational researchViral infection
10.1038/S41467-025-63972-4
ISSN:2041-1723

COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer

Neil H. SegalJeanne TieScott KopetzMichel DucreuxEric Chen16
British Journal Of Cancer
2024
2024/7/25
00 p.1-9
To determine whether the addition of durvalumab (anti-PD-L1) and oleclumab (anti-CD73) to standard-of-care treatment (FOLFOX and bevacizumab) enhances the anti-tumour effect in patients with metastatic colorectal cancer (mCRC). COLUMBIA-1 (NCT04068610) was a Phase Ib (feasibility; Part 1)/Phase II (...
Cancer immunotherapyColon cancerTumour biomarkers
10.1038/S41416-024-02796-3
ISSN:0007-0920

Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort

Xichun HuQingyuan ZhangTao SunHuihua XiongWei Li24
Nature Communications
2025
2025/5/9
Vol.16 No.1 p.1-12
In the global CAPItello-291 randomized phase 3 study (NCT04305496) in patients with hormone receptor-positive/HER2-negative advanced breast cancer and progression during/after aromatase inhibitor treatment, capivasertib–fulvestrant significantly improved progression-free survival (PFS) in the overal...
Breast cancerCancer therapyTumour biomarkers
10.1038/S41467-025-59210-6
ISSN:2041-1723

A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis

Philip N. NewsomeArun J. SanyalGuy NeffJörn M. SchattenbergVlad Ratziu10
Nature Communications
2023
2023/11/6
Vol.14 No.1 p.1-11
Non-alcoholic steatohepatitis (NASH) is a progressive, inflammatory liver disease with no approved pharmacological treatment. This Phase IIa, double-blind, placebo-controlled, multicentre trial (ClinicalTrials.gov: NCT03166735) investigated pharmacodynamics and safety of BI 1467335, an amine oxidase...
Clinical pharmacologyNon-alcoholic steatohepatitis
10.1038/S41467-023-42398-W
ISSN:2041-1723

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Benjamin BesseElvire Pons-TostivintKeunchil ParkSylvia HartlPatrick M. Forde38
Nature Medicine
2024
2024/2/13
00 p.1-14
For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance...
Non-small-cell lung cancerTumour biomarkers
10.1038/S41591-024-02808-Y
ISSN:1078-8956

Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine

Holly JanesYouyi FongYing HuangDavid BenkeserElizabeth J. Kelly31
Npj Vaccines
2026
2026/4/18
0
In the phase 3 AZD1222 COVID-19 vaccine trial, anti-Spike (vaccine-matched and Delta) binding IgG antibody concentration and neutralizing antibody (nAb) titer (vaccine-matched+D614G and Delta), measured four weeks post-dose two (D57), were assessed as correlates of risk of severe COVID-19 and Delta ...
DiseasesImmunologyMedical researchMicrobiology
10.1038/S41541-026-01411-1
ISSN:2059-0105

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

Peter SchmidSeock-Ah ImZbigniew NoweckiPiotr J. WysockiJacek Jassem12
Nature Cancer
2026
2026/6/8
00 p.1-10
More effective therapies are required for advanced breast cancer. We report results from 58 women with locally advanced unresectable or metastatic hormone-receptor (HR)-negative, human epidermal growth factor receptor 2 (HER2)-low breast cancer enrolled in arm 6 of the multicenter, open-label phase ...
Breast cancerCancerDrug developmentTumour biomarkers
10.1038/S43018-026-01181-8
ISSN:2662-1347

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial

Princess U. OgboguFlorence RoufossePraveen AkuthotaPiotr KunaMatthieu Groh22
Nature Medicine
2026
2026/3/31
00 p.1-9
Benralizumab, an eosinophil-depleting anti-IL-5 receptor α antibody, has demonstrated efficacy in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis and shown promising results in hypereosinophilic syndrome (HES). NATRON was a randomized, double-blind placebo-controlled pha...
ImmunologyMedical research
10.1038/S41591-026-04315-8
ISSN:1078-8956